Sort
48,018 grants matching “immunotherapy”
Determinants of immunotherapy response in NASH-Hepatocellular carcinoma
$455,518Josep M Llovet · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · CA
In Vivo Analysis of T lymphocytes in the Persistently Infected CNS
$455,501Michael B Oldstone · Scripps Research Institute, The · R01 · FY2011 · AI
Regulation of T cell-mediated T1D: The role of T follicular helper cells
$455,491Roland Michael Tisch · Univ Of North Carolina Chapel Hill · R01 · FY2025 · DK
Identifying and targeting neoantigens in aggressive salivary carcinomas
$455,430Luc Gordon Trang Morris · Sloan-Kettering Inst Can Research · R01 · FY2022 · DE
Investigating the neutrophil-sensory neuron crosstalk in lung cancer
$455,419Chengcheng Jin · University Of Pennsylvania · R01 · FY2024 · CA
An innate immune checkpoint in cancer immunotherapy
$455,406Carla Rothlin · Yale University · R01 · FY2017 · CA
Head & Neck Cancer Neoantigen Characterization & Therapeutic Targeting
$455,401Michael Korrer · Vanderbilt University Medical Center · R01 · FY2021 · DE
EXPRESSION OF TUBERCULOSIS IN THE LUNG
$455,392Univ Of Med/Dent Of Nj-Nj Medical School · R01 · FY2003 · HL
Sublingual Supramolecular Vaccines and Immunotherapies
$455,338Joel H Collier · Duke University · R01 · FY2025 · AI
Inflammation and immunity in the crucible of premalignancy
$455,336Adrian Erlebacher · University Of California, San Francisco · R01 · FY2016 · CA
Inflammation and immunity in the crucible of premalignancy
$455,336Adrian Erlebacher · University Of California, San Francisco · R01 · FY2017 · CA
Project 3: Myeloid-lymphoid cell crosstalk in HNSCC therapy
$455,328Mikael Pittet · Massachusetts General Hospital · P01 · FY2022 · CA
Regulation of Tumor Immunogenicity in Glioblastoma
$455,315Sze Chun Winson Ho · University Of California, San Francisco · R01 · FY2023 · NS
Regulation of Tumor Immunogenicity in Glioblastoma
$455,315Sze Chun Winson Ho · University Of California, San Francisco · R01 · FY2025 · NS
Developing new therapeutic strategies for pediatric tumors that lack clinically actionable mutations
$455,194Paul Geeleher · St. Jude Children'S Research Hospital · R01 · FY2024 · CA
Resolving Spatiotemporal Dynamics of Recombinant Poliovirus Immunotherapy
$455,171Matthias Gromeier · Duke University · R01 · FY2025 · CA
Neoadjuvant immunotherapy approaches to early stage melanoma
$455,161Meenhard Herlyn · Wistar Institute · P50 · FY2024 · CA
Novel immune suppressive activities of Fas/CD95 in triple negative breast cancer
$455,145Marcus E Peter · Northwestern University At Chicago · R01 · FY2024 · CA
Secretable theranostic payloads to augment the efficacy of adoptive CAR-T cell therapies
$455,112Vladimir Ponomarev · Sloan-Kettering Inst Can Research · R21 · FY2020 · CA
Quantitative single-cell biomarkers of T-cells to optimize tumor immunotherapy
$455,093Navin Varadarajan · University Of Houston · R01 · FY2015 · CA
E2A/HEB MEDIATED TRANSCRIPTIONAL REGULATION IN T CELL DEVELOPMENT
$455,072Yuan Zhuang · Duke University · R01 · FY2019 · GM
E2A/HEB MEDIATED TRANSCRIPTIONAL REGULATION IN T CELL DEVELOPMENT
$455,072Yuan Zhuang · Duke University · R01 · FY2020 · GM
E2A/HEB MEDIATED TRANSCRIPTIONAL REGULATION IN T CELL DEVELOPMENT
$455,072Francis Ka-Ming Chan · Duke University · R01 · FY2021 · GM
Exploring novel strategies for immunoprevention of estrogen receptor negative breast cancer
$455,035Dihua Yu · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Metabolic checkpoint in dendritic cell subsets and adaptive immunity
$455,000Hongbo Chi · St. Jude Children'S Research Hospital · R37 · FY2025 · AI